560 related articles for article (PubMed ID: 9816329)
1. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
2. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
3. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
4. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
[TBL] [Abstract][Full Text] [Related]
5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
6. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
8. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
[TBL] [Abstract][Full Text] [Related]
9. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
11. Human TNF mutants with selective activity on the p55 receptor.
Van Ostade X; Vandenabeele P; Everaerdt B; Loetscher H; Gentz R; Brockhaus M; Lesslauer W; Tavernier J; Brouckaert P; Fiers W
Nature; 1993 Jan; 361(6409):266-9. PubMed ID: 8380906
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
[TBL] [Abstract][Full Text] [Related]
13. Selective formation of tumor necrosis factor-alpha (TNF) degradation products contributes to TNF mediated cytotoxicity.
Fruehauf JP; Sinha BK
Oncol Res; 1992; 4(3):91-101. PubMed ID: 1319775
[TBL] [Abstract][Full Text] [Related]
14. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
Dettke M; Loibner H
Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
[TBL] [Abstract][Full Text] [Related]
15. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha.
Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
Biotechnol Appl Biochem; 2006 Mar; 43(Pt 3):137-45. PubMed ID: 16293104
[TBL] [Abstract][Full Text] [Related]
16. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
17. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
18. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
Kim S; Cheung LH; Zhang W; Rosenblum MG
Appl Microbiol Biotechnol; 2007 Nov; 77(1):99-106. PubMed ID: 17703297
[TBL] [Abstract][Full Text] [Related]
19. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
[TBL] [Abstract][Full Text] [Related]
20. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.
Huang TH; Morrison SL
J Pharmacol Exp Ther; 2006 Mar; 316(3):983-91. PubMed ID: 16291729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
